Nanoliposomal anti-PCSK9 vaccine induces long-term and safe protection against atherosclerosis in C57BL/6 mouse.

Back

ESC Premium Access

Nanoliposomal anti-PCSK9 vaccine induces long-term and safe protection against atherosclerosis in C57BL/6 mouse.

Session: Poster Session 7 - Lipids

Topic: Drug therapy

Speaker: Professor M. Banach (Lodz, PL)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Maciej Banach

Medical University of Lodz, Lodz (Poland)

8 presentations

2 followers

14 more presentations in this session

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plasma levels are associated with the metabolic syndrome in patients with stable coronary artery disease

Speaker: Doctor C. Caselli (Pisa, IT)

Access

Abstract

Slides

Effects of evolocumab on LDL-C by race and ethnicity: an analysis of double-blind and open-label extension studies

Speaker: Doctor C. Rodriguez (The Bronx, US)

Access

Abstract

Dalcetrapib reduces incident diabetes in patients with recent acute coronary syndrome

Speaker: Professor G. Schwartz (Aurora, US)

Access

Abstract

Therapeutic effect of nanoliposomal anti-PCSK9 vaccine on hypercholesterolemia and atherosclerosis in C57BL/6 mice.

Speaker: Professor M. Banach (Lodz, PL)

Access

Abstract

Slides

Lipoprotein (a) and cardiovascular risk: are women at increased risk?

Speaker: Doctor M. Santos (Funchal, PT)

Access

Abstract

Slides

Access the full session

Poster Session 7 - Lipids

Speakers: Professor M. Banach, Doctor C. Caselli, Doctor C. Rodriguez, Professor G. Schwartz, Professor M. Banach...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources